(Q51134580)
Statements
Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. (English)
1 reference
National Cancer Institute of Canada Clinical Trials Group
1 reference
J A Maroun
1 reference
K Belanger
1 reference
L Seymour
1 reference
S Matthews
1 reference
J Roach
1 reference
J Dionne
1 reference
D Soulieres
1 reference
D Stewart
1 reference
R Goel
1 reference
D Charpentier
1 reference
G Goss
1 reference
E Tomiak
1 reference
J Yau
1 reference
J Jimeno
1 reference
G Chiritescu
1 reference
1 September 2006
1 reference
17
1 reference
9
1 reference
1371-1378
1 reference